Hosted on MSN23h
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted TherapyCNTX has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. This experimental treatment is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback